Cold Spring Harbor Symposia on Quantitative Biology
2018
Yihui Cui, Yan Yang, Yiyan Dong et al.
preprint
The rapid antidepressant effect of ketamine is arguably one of the most significant advances in the mental health field in the last half century. However, its mechanism of action has remained elusive. Here, we describe our latest discovery on how ketamine blocks N-methyl-D-aspartate receptor (NMDAR)-dependent burst firing of an "antireward" center in the brain, the lateral habenula (LHb), to...
Journal of Drug and Alcohol Research
2018
Bruk Getachew, Yousef Tizabi
17 citations
The co-morbidity between heavy drinking and depression can negatively influence successful cessation of alcohol use. Since ketamine, a glutamatergic NMDA receptor antagonist, has shown promise as a quick-acting antidepressant, we studied its effects specifically on alcohol withdrawal-induced depression. We also evaluated the effects of NBQX an AMPA/kainate receptor antagonist, because some of...
Brazilian Journal of Psychiatry
2018
Ivan Y. Barenboim, Beny Lafer
8 citations
DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.
Restorative Neurology and Neuroscience
2018
Madhuri R Tolahunase, Rajesh Sagar, Muneeb Faiq et al.
Current interventions for major depressive disorder (MDD) are suboptimal, and only one third respond to them on initial treatment. Neuroplasticity theories are the basis for several emerging treatments. Evidence on the impact of yoga, a well-known mind-body intervention, on neuroplasticity in MDD is limited. To determine the effects of 12-week yoga- and meditation-based lifestyle intervention...
The Lancet Psychiatry
2018
Brooke L Short, J. Fong, Verònica Gálvez et al.
551 citations
This is the first systematic review of the safety of ketamine in the treatment of depression after single and repeated doses. We searched MEDLINE, PubMed, PsycINFO, and Cochrane Databases and identified 288 articles, 60 of which met the inclusion criteria. After acute dosing, psychiatric, psychotomimetic, cardiovascular, neurological, and other side-effects were more frequently reported after...
December 28, 2017
V. Whizar-Lugo, Cesar Heredia-Mota, R. Camacho
Major depression (MD) is a very common chronic mental illness that causes substantial disability in millions of adolescents and adults throughout the world. In the United States of North America there is an annual risk of depression of 6.6%. Unfortunately, only 30-40% of patients will remit with the usual antidepressant drugs and there is a high risk of suicide attempts during the first month...
JAMA Psychiatry
December 27, 2017
Ella Daly, Jaskaran Singh, Maggie Fedgchin et al.
708 citations
Importance: Approximately one-third of patients with major depressive disorder (MDD) do not respond to available antidepressants. Objective: To assess the efficacy, safety, and dose-response of intranasal esketamine hydrochloride in patients with treatment-resistant depression (TRD). Design, Setting, and Participants: This phase 2, double-blind, doubly randomized, delayed-start,...
Neuropharmacology
December 27, 2017
Leor Roseman, Lysia Demetriou, Matthew B. Wall et al.
239 citations
Recent evidence indicates that psilocybin with psychological support may be effective for treating depression. Some studies have found that patients with depression show heightened amygdala responses to fearful faces and there is reliable evidence that treatment with SSRIs attenuates amygdala responses (Ma, 2015). We hypothesised that amygdala responses to emotional faces would be altered...
Shanghai archives of psychiatry
December 25, 2017
Shikai Wang, Mincai Qian, Liang Li et al.
Depression is a highly prevalent and severely disabling disease. The treatment effects, intensity and onset time of antidepressants have been highlighted in many studies. Recent studies on the rapid-onset of antidepressant response focused on the effect of a single low dose of intravenous ketamine. However, there are still some problems with treatment, including safety, efficacy, ethics, dose,...
Trials
December 22, 2017
Richard M Stewart, Janice W Y Wong, Kevin C Runions et al.
The first line of pharmacological treatment for severe depressive disorders in young people is selective serotonin reuptake inhibitors (SSRIs). However, beneficial clinical effects are rarely observed before several weeks into treatment. Nitrous oxide (N2O) has a long-standing safety record for pain relief and has been used in adults and young people. In adults with severe treatment-resistant...